Oncolytic herpes virus induces effective anti-cancer immunity against murine colon cancer

Hepato-Gastroenterology

Volumn 58, Issue 110-111, 2011, Pages 1482-1489

  Shirota, Takashi ^a   Kasuya, Hideki ^a   Kodera, Yasuhiro ^a   Nishikawa, Yoko ^a   Shikano, Toshio ^a   Sahin, Tevfik Tolga ^a   Gewen, Tan ^a   Yamamura, Kazuo ^a   Fukuda, Saori ^a   Kanzaki, Akiyuki ^a   Yamada, Suguru ^a   Fujii, Tsutomu ^a   Sugimoto, Hiroyuki ^a   Nomoto, Shuji ^a   Takeda, Shin ^a   Nakao, Akimasa ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

5 FU; Anti cancer immunity; Colon cancer; HSV; Oncolytic herpes virus therapy

Indexed keywords

CD68 ANTIGEN; FLUOROURACIL; ONCOLYTIC HERPES VIRUS;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD CELL COUNT; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; COLON CANCER; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; GROWTH RATE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOFLUORESCENCE; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR VOLUME;

EID: 83355163508     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge11168     Document Type: Article

References (68)

1. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274:373-376. (Pubitemid 26353341)
2. Ganly I, Kirn D, Eckhardt G, Rodriguez GI, Soutar DS, Otto R, Robertson AG, Park O, Gulley ML, Heise C, Von Hoff DD, Kaye SB: A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 2000; 6:798-806. (Pubitemid 30159332)
3. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, et al.: Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000; 7:867-874. (Pubitemid 30303584)
4. Markert JM, Liechty PG, Wang W, Gaston S, Braz E, Karrasch M, et al.: Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther 2009; 17:199-207.
5. Papanastassiou V, Rampling R, Fraser M, Petty R, Hadley D, Nicoll J, et al.: The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther 2002; 9:398-406. (Pubitemid 34414038)
6. Harrow S, Papanastassiou V, Harland J, Mabbs R, Petty R, Fraser M, et al.: HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma:safety data and long-term survival. Gene Ther 2004; 11:1648-1658. (Pubitemid 39530101)
7. Fujimoto Y, Mizuno T, Sugiura S, Goshima F, Kohno S, Nakashima T, et al.: Intratumoral injection of herpes simplex virus HFlO in recurrent head and neck squamous cell carcinoma. Acta Otolaryngol 2006; 126:1115-1117. (Pubitemid 44272841)
8. Nakao A, Kimata H, Imai T, Kikumori T, Teshigahara O, Nagasaka T, et al.: Intratumoral injection of herpes simplex virus HFlO in recurrent breast cancer. Ann Oncol 2004; 15:988-989. (Pubitemid 39004359)
9. Kimata H, Imai T, Kikumori T, Teshigahara O, Nagasaka T, Goshima F, et al.: Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HFlO) against recurrent metastatic breast cancer. Ann Surg Oncol 2006; 13:1078-1084. (Pubitemid 44337967)
10. Nakao A, Takeda S, Shimoyama S, Kasuya H, Kimata H, Teshigahara O, et al.: Clinical experiment of mutant herpes simplex virus HF10 therapy for cancer. Curr Cancer Drug Targets 2007; 7:169-174. (Pubitemid 46348631)
11. Zhang YQ, Tsai YC, Monie A, Wu TC, Hung CF: Enhancing the therapeutic effect against ovarian cancer through a combination of viral oncolysis and antigen-specific immunotherapy. Mol Ther 2010; 18:692-699.
12. Galivo F, Diaz RM, Wongthida P, Thompson J, Kottke T, Barber G, Melcher A, Vile R: Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma. Gene Ther 2010; 17:158-170.
13. Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S: Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 2010; 17:718-730.
14. Gil M, Bieniasz M, Wierzbicki A, Bambach BJ, Rokita H, Kozbor D: Targeting a mimotope vaccine to activating Fcgamma receptors empowers dendritic cells to prime specific CD8+Tcell responses in tumor-bearing mice.J Immunol 2009; 83:6808-6818.
15. Markert JM, Malick A, Coen DM, Martuza RL: Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery 1993; 32:597-603. (Pubitemid 23099525)
16. Detta A, Harland J, Hanif I, Brown SM, Cruickshank G: Proliferative activity and in vitro replication of HSV1716 in human metastatic brain tumours. J Gene Med 2003; 5:681-689. (Pubitemid 40309706)
17. Iacopetta B: Methyl-group metabolism and the response of colorectal cancer to 5-flu- orouracil. Crit Rev Oncog 2006; 12:115-126.
18. Temmink OH, Comijn EM, Fukushima M, Peters GJ: Intracellular thymidylate sy- nthase inhibition by trifluorothymidine in FM3A cells. Nucleosides Nucleotides Nucleic Acids 2004; 23:1491-1494. (Pubitemid 39625949)
19. Sijens PE, Ng TC: Thymidine-modulated 5-fluorouracil metabolism in liver and RIF- 1 tumors studied by 19F magnetic resonance spectroscopy. Magn Reson Imaging 1992; 10:385-392.
20. Vercammen-Grandjean AF, Arnould R, Libert A, Lejeune FJ: Effects of 5- fluor- ouracil on various melanoma cell metabolisms. Its use for assessing the cold thymidi- ne pool. Anticancer Res 1982; 2:133-140.
21. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, Martin F, Apetoh L, Rébé C, Ghiringhelli F: 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 2010; 70:3052-3061.
22. Rodriguez PC, Hernandez CP, Quiceno D, Dubinett SM, Zabaleta J, Ochoa JB, Gilbert J, Ochoa AC: Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 2005; 202:931-939. (Pubitemid 41396893)
23. Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, Herber DL, Schneck J, Gabrilovich DI: Altered recognition of antigen is a mechanism of CD8+T cell tolerance in cancer. Nat Med 2007; 13:828-835. (Pubitemid 47038194)
24. Kusmartsev S, Gabrilovich DI: Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. J Leukoc Biol 2003; 74:186-196. (Pubitemid 38040415)
25. Bridle BW, Hanson S, Lichty BD: Combining oncolytic virotherapy and tumour vaccination. Cytokine Growth Factor Rev 2010; 21:143-148.
26. Sinkovics JG, Horvath JC: Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers. Arch Immunol Ther Exp (Warsz) 2008; 56:3s-59s.
27. Schierer S, Hesse A, Müller I, Kämpgen E, Curiel DT, Schuler G, Steinkasserer A, Nettelbeck DM: Modulation of viability and maturation of human monocyte-derived dendritic cells by oncolytic adenoviruses. Int J Cancer 2008; 122:219-229. (Pubitemid 350209999)
28. Dzojic H, Loskog A, Tötterman TH, Essand M: Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model. Prostate 2006; 66:831-838.
29. An WW, Kanazawa Y, Ozawa M, Nakaya K, Saito T, Tanaka A, Bradley WG: Dendritic cell differentiation and tumor cell apoptosis induced by components of a polyphenylpropanoid polysaccharide complex. Anticancer Res 2010; 30:613-622.
30. Cui J, Lin AL, Liu Q, Sun Q, Gao ZH: Dendritic cells transfected with lentiviral vector-encoding human granulocyte-macrophage colony-stimulating factor augment anti-tumour T-cell response in vitro. Int J Immunogenet 2010 (Epub ahead of print).
31. Chen F, Hou M, Ye F, Lv W, Xie X: Ovarian cancer cells induce peripheral mature dendritic cells to differentiate into macrophagelike cells in vitro. Int J Gynecol Cancer 2009; 19:1487-1493.
32. He J, Yin Y, Luster TA, Watkins L, Thorpe PE: Antiphosphatidylserine antibody combined with irradiation damages tumor blood vessels and induces tumor immunity in a rat model of glioblastoma. Clin Cancer Res 2009; 15:6871-6880.
33. Chang JW, Hsieh JJ, Shen YC, Ho E, Chuang CK, Chen YR, Liao SK, Chen JS, Leong SP, Hou MM, Chang NJ, Wang CH: Immunotherapy with dendritic cells pulsed by autologous dactinomycin-induced melanoma apoptotic bodies for patients with malignant melanoma. Melanoma Res 2009; 19:309-315.
34. Liu QL, Wang YS, Wang J X: Effect of insulin on functional status of cord blood-derived dendritic cells and on dendritic cell-induced CTL cytotoxicity against pancreatic cancer cell lines.Hepatobiliary Pancreat Dis Int 2009; 8:529-534.
35. Hummel JL, Safroneeva E, Mossman KL: The role of ICP0-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma. Mol Ther 2005; 12:1101-1110. (Pubitemid 41723044)
36. Li H, Dutuor A, Fu X, Zhang X: Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model. J Gene Med 2007; 9:161-169. (Pubitemid 46523534)
37. Nakamori M, Fu X, Rousseau R, Chen SY, Zhang X: Destruction of nonimmunogenic mammary tumor cells by a fusogenic oncolytic herpes simplex virus induces potent antitumor immunity. Mol Ther 2004; 9:658-665. (Pubitemid 38660418)
38. Li H, Dutuor A, Tao L, Fu X, Zhang X: Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma. Clin Cancer Res 2007; 13:316-322. (Pubitemid 46121885)
39. Endo T, Toda M, Watanabe M, et al.: In situ cancer vaccination with a replicationconditional HSV for the treatment of liver metastasis of colon cancer. Cancer Gene Ther 2002; 9:142-148. (Pubitemid 34141916)
40. Toda M, Rabkin SD, Kojima H, Martuza RL: Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther 1999; 10:385-393. (Pubitemid 29097317)
41. Diaz RM, Galivo F, Kottke T, et al.: Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res 2007; 67:2840-2848. (Pubitemid 46548974)
42. Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S: Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 2010; 17:718-730.
43. Prestwich RJ, Errington F, Ilett EJ, et al.: Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res 2008; 14:7358-7366.
44. Di Paolo NC, Tuve S, Ni S, Hellstrom KE, Hellstrom I, Lieber A: Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with lowdose cyclophosphamide treatment on antitumor immune responses. Cancer Res 2006; 66 (2):960-969. (Pubitemid 43165964)
45. Bennett CL, Christie J, Ramsdell F, et al.: The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001; 27:20-21. (Pubitemid 32044513)
46. Wildin RS, Ramsdell F, Peake J, et al.: X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001; 27:18-20. (Pubitemid 32044512)
47. Brunkow ME, Jeffery EW, Hjerrild KA, et al.: Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001; 27:68-73. (Pubitemid 32044521)
48. Lapteva N, Aldrich M, Rollins L, et al.: Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity. Mol Ther 2009; 17:1626-1636.
49. Fishman M: A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer. Exp Opin Biol Ther 2009; 9:1565-1575.
50. Miyazawa M, Ohsawa R, Tsunoda T, et al.: Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci 2010; 101:433-439
51. Lubaroff DM, Konety BR, Link B, et al.: Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. Clin Cancer Res 2009; 15:7375-7380.
52. Gridelli C, Rossi A, Maione P, Ferrara ML, Castaldo V, Sacco PC: Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy. Oncologist 2009; 1:909-920.
53. Ho VT, Vanneman M, Kim H, et al.: Biologic activity of irradiated, autologous, GMCSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc Natl Acad Sci USA 2009; 106:15825-15830.
54. McNeel DG, Dunphy EJ, Davies JG, et al.: Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage DO prostate cancer. J Clin Oncol 2009; 27:4047-4054.
55. Weide B, Pascolo S, Scheel B, et al.: Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother 2009; 32:498-507.
56. Rech AJ, Vonderheide RH: Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci 2009; 1174:99-106.
57. Schirrmacher V, Bai L, Umansky V, Yu L, Xing Y, Qian Z: Newcastle disease virus activates macrophages for anti-tumor activity. Int J Oncol 2000; 16:363-373.
58. Ockert D, Schirrmacher V, Beck N, Stoelben E, Ahlert T, Flechtenmacher J, Hagmüller E, Buchcik R, Nagel M, Saeger HD: Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin Cancer Res 1996; 2:21-28. (Pubitemid 26042174)
59. Schirrmacher V, Haas C, Bonifer R, Ertel C: Virus potentiation of tumor vaccine T -cell stimulatory capacity requires cell surface binding but not infection. Clin Cancer Res 1997; 3:1135-1148. (Pubitemid 27319760)
60. Schlag P, Manasterski M, Gerneth T, Hohenberger P, Dueck M, Herfarth C, Liebrich W, Schirrmacher V: Active specific immunotherapy with Newcastle-disease virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial. Cancer Immunol Immunother 1992; 35:325-330.
61. Ohkusu-Tsukada K, Ohta S, Kawakami Y, Toda M: Adjuvant effects of formalin-inactivated HSV through activation of dendritic cells and inactivation of myeloid-derived suppressor cells in cancer immunotherapy. Int J Cancer 2010.(Epub ahead of print)
62. Sivendran S, Pan M, Kaufman HL, Saenger Y: Herpes simplex virus oncolytic vaccine therapy in melanoma. Expert Opin Biol Ther 2010. (Epub ahead of print)
63. Cerullo V, Pesonen S, Diaconu I, Escutenaire S, Arstila PT, Ugolini M, Nokisalmi, P, Raki M, Laasonen L, Särkioja M, Rajecki M, Kangasniemi L, Guse K, Helminen A, Ahtiainen L, Ristimäki A, Räisänen-Sokolowski A, Haavisto E, Oksanen M, Karli E, Karioja-Kallio A, Holm SL, Kouri M, Joensuu T, Kanerva A, Hemminki A: Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res 2010; 70:4297-4309.
64. Merrick AE, Ilett EJ, Melcher AA: JX-594, a targeted oncolytic poxvirus for the treatment of cancer. Curr Opin Investig Drugs 2009; 10:1372-1382.
65. Lee JH, Roh MS, Lee YK, Kim MK, Han JY, Park BH, Trown P, Kirn DH, Hwang TH: Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model. Cancer Gene Ther 2010; 17:73-79.
66. Chang J, Zhao X, Wu X, Guo Y, Guo H, Cao J, Guo Y, Lou D, Yu D, Li J: A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colony stimulating factor: armed oncolytic adenovirus for the treatment of head and neck cancers. Cancer Biol Ther 2009; 8:676-82.
67. Janke M, Peeters B, Leeuw O, Moorman R, Arnold A, Fournier P, Schirrmacher V: Recombinant New-castle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy. Gene Ther 2007; 14:1639-1649. (Pubitemid 350143189)
68. Kohno SI, Luo C, Nawa A, Fujimoto Y, Watanabe D, Goshima F, Tsurumi T, Nishiyama Y: Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus. Cancer Gene Ther 2007; 14:918-926. (Pubitemid 47558955)